Casey Tansey

Casey Tansey joined USVP as a general partner in April 2005. A veteran of the medical device industry， Casey brings over 25 years of entrepreneurial， early-stage medical device and seasoned operating experience to USVP.

Casey's investment strategy is a lot like his strategy as a CEO: identify unmet clinical needs where patients are in need of new and improved products and services. At USVP， Casey will focus on the trend toward the miniaturization of devices and the development of minimally-invasive technologies that promise innovations in the delivery of medical products and services， especially in cardiovascular products， orthopedics， spinal care and neurology.

Casey's passion is to strive for delivery of medical services with less trauma to the patient and improved quality of life. Innovations shaping this trend include minimally-invasive technologies. During his tenure as CEO and President of Epicor Medical from 2001 to 2004， Casey， along with a dedicated team， pioneered a minimally-invasive treatment for atrial fibrillation and transformed the company into a recognized market leader. He led Epicor's acquisition by St. Jude Medical at a valuation of more than $200 million.

Prior to Epicor， Casey was CEO and President of Heartport， a public company that helped pioneer minimally-invasive cardiac surgery which is now a Johnson & Johnson company. Before that， he was with Baxter Edward's Cardiovascular Division for nearly ten years， holding various sales and marketing positions. During his tenure at Baxter， Casey was involved in launching innovative heart valve products that have grown to be the market leaders. Casey serves on the Board of Directors for ApniCure， CardioKinetix， Devax， Inspire Medical， Intersect ENT， Intuity Medical， Nanostim， ReShape Medical， and SentreHEART. In addition， he served as the Chairman of the Board of Directors of the World Heart Foundation， an organization dedicated to advancing humanitarian efforts in heart surgery worldwide through education and collaborati